Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
2.870
-0.060 (-2.05%)
At close: Jul 19, 2024, 4:00 PM
2.980
+0.110 (3.83%)
Pre-market: Jul 22, 2024, 8:36 AM EDT
Acumen Pharmaceuticals Employees
As of December 31, 2023, Acumen Pharmaceuticals had 52 total employees, including 51 full-time and 1 part-time employees. The number of employees increased by 12 or 30.00% compared to the previous year.
Employees
52
Change (1Y)
12
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,075,712
Market Cap
172.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 52 | 12 | 30.00% |
Dec 31, 2022 | 40 | 23 | 135.29% |
Dec 31, 2021 | 17 | 10 | 142.86% |
Dec 31, 2020 | 7 | - | - |
Related Stocks
Company Name | Employees |
---|---|
OrganiGram Holdings | 984 |
Metagenomi | 236 |
Puma Biotechnology | 185 |
Rigel Pharmaceuticals | 147 |
Adverum Biotechnologies | 121 |
MediWound | 100 |
Syros Pharmaceuticals | 68 |
Fennec Pharmaceuticals | 29 |
ABOS News
- 2 months ago - Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference - GlobeNewsWire
- 2 months ago - Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference - GlobeNewsWire
- 2 months ago - Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024 - GlobeNewsWire
- 3 months ago - Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 3 months ago - Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 4 months ago - Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights - GlobeNewsWire